XML 49 R37.htm IDEA: XBRL DOCUMENT v3.19.1
Commitments and Contingencies - Additional Information (Detail)
 1 Months Ended 3 Months Ended
Dec. 05, 2018
USD ($)
Apr. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Feb. 28, 2018
USD ($)
Mar. 31, 2017
USD ($)
Country
Mar. 31, 2019
USD ($)
Patent
Mar. 31, 2018
USD ($)
Commitments And Contingencies [Line Items]              
Milestone payments     $ 75,000        
License fee           $ 112,500 $ 100,000
ADVA Tec Agreement [Member]              
Commitments And Contingencies [Line Items]              
Number of patents issued | Patent           9  
Number of pending US patent applications | Patent           1  
Number of patents granted | Patent           59  
Number of patent applications in other major markets | Patent           4  
Licensing Agreements [Member] | ADVA Tec Agreement [Member] | Ovaprene [Member]              
Commitments And Contingencies [Line Items]              
Agreement termination period on failing to commercialize in certain designated countries         3 years    
Agreement termination on failing to enroll patient within months of production and release         6 months    
Prior written notice period for termination of agreement for both parties       60 days      
Licensing Agreements [Member] | ADVA Tec Agreement [Member] | Minimum [Member]              
Commitments And Contingencies [Line Items]              
Number of designated European countries | Country         3    
Percentage of royalty rate         1.00%    
Licensing Agreements [Member] | ADVA Tec Agreement [Member] | Minimum [Member] | Ovaprene [Member]              
Commitments And Contingencies [Line Items]              
Minimum spending amounts per year         $ 5,000,000    
Licensing Agreements [Member] | ADVA Tec Agreement [Member] | Maximum [Member]              
Commitments And Contingencies [Line Items]              
Percentage of royalty rate         10.00%    
Juniper Pharmaceuticals, Inc. [Member]              
Commitments And Contingencies [Line Items]              
Potential annual license maintenance fee, payments in year one   $ 50,000          
Potential annual license maintenance fee payments, thereafter   $ 100,000          
License agreement, period of continuation from date of first commercial sale of product or process   10 years          
License agreement notice period of termination for breach of payment obligation   30 days          
Period of dismissal of bankruptcy petition   90 days          
License agreement notice period of termination for breach of other obligation   60 days          
License agreement, notice period of termination   180 days          
Juniper Pharmaceuticals, Inc. [Member] | Clinical And Regulatory Milestones [Member]              
Commitments And Contingencies [Line Items]              
Maximum potential milestone payments   $ 13,500,000          
Juniper Pharmaceuticals, Inc. [Member] | Sales Milestones [Member]              
Commitments And Contingencies [Line Items]              
Maximum potential milestone payments   $ 30,300,000          
Juniper Pharmaceuticals [Member]              
Commitments And Contingencies [Line Items]              
License agreement, termination period prior to receipt of approval   90 days          
Upfront license fee paid   $ 250,000          
SST [Member]              
Commitments And Contingencies [Line Items]              
License agreement, termination period due to performance failure         60 days    
Percentage of rights to inventions by employees under license agreement       50.00%      
License agreement, expiration period       10 years      
License agreement, termination period prior to receipt of approval       90 days      
License agreement, termination period after receipt of approval       180 days      
License agreement, termination period for applicable license products of applicable countries       30 days      
SST [Member] | Minimum [Member]              
Commitments And Contingencies [Line Items]              
Milestone payments, contingent amount       $ 500,000.0      
Secured investment required for license agreement       10,000,000      
SST [Member] | Maximum [Member]              
Commitments And Contingencies [Line Items]              
Milestone payments, contingent amount       $ 18,000,000      
SST [Member] | License And Collaboration Agreement [Member]              
Commitments And Contingencies [Line Items]              
Percentage of rights to inventions by employees under license agreement       50.00%      
Orbis [Member] | Development And Option Agreement [Member]              
Commitments And Contingencies [Line Items]              
Milestone payments     $ 300,000        
Commencement period for stage two upon achievement of stage one     90 days        
MilanaPharm [Member] | Licensing Agreements [Member]              
Commitments And Contingencies [Line Items]              
License fee $ 25,000            
License fee to be paid upon contingency 200,000            
Proceeds raised from equity financing 10,000,000            
Hammock Pharmaceuticals, Inc. [Member] | Assignment Agreement [Member]              
Commitments And Contingencies [Line Items]              
License fee 250,000            
License fee to be paid upon contingency 250,000            
Proceeds raised from equity financing 10,000,000            
Upon Achieving Certain Commercial Milestones [Member] | SST [Member] | License And Collaboration Agreement [Member] | Maximum [Member]              
Commitments And Contingencies [Line Items]              
Milestone payments, contingent amount       $ 100,000,000      
Upon Achieving Certain Commercial Milestones [Member] | MilanaPharm [Member] | Licensing Agreements [Member] | Maximum [Member]              
Commitments And Contingencies [Line Items]              
Milestone payments, contingent amount 1,750,000            
Upon Signing Of Development And Option Agreement [Member] | Orbis [Member] | Development And Option Agreement [Member]              
Commitments And Contingencies [Line Items]              
Milestone payments     $ 150,000        
Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member] | Orbis [Member] | Development And Option Agreement [Member]              
Commitments And Contingencies [Line Items]              
Milestone payments     $ 75,000        
Upon Achieving Certain Development Milestones [Member] | MilanaPharm [Member] | Licensing Agreements [Member] | Maximum [Member]              
Commitments And Contingencies [Line Items]              
Milestone payments, contingent amount 300,000            
Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] | Hammock Pharmaceuticals, Inc. [Member] | Assignment Agreement [Member] | Maximum [Member]              
Commitments And Contingencies [Line Items]              
Milestone payments, contingent amount $ 1,100,000            
Upon Achievement Of Specified Development And Regulatory Milestones [Member] | ADVA Tec Agreement [Member] | Maximum [Member]              
Commitments And Contingencies [Line Items]              
Milestone payments           $ 14,600,000  
Upon Achievement Of Specified Development And Regulatory Milestones [Member] | Licensing Agreements [Member] | ADVA Tec Agreement [Member] | Maximum [Member]              
Commitments And Contingencies [Line Items]              
Milestone payments         $ 14,600,000    
Upon Reaching Certain Worldwide Net Sales Milestones [Member] | Licensing Agreements [Member] | ADVA Tec Agreement [Member]              
Commitments And Contingencies [Line Items]              
Milestone payments         $ 20,000,000    
Upon Achievement Of Specified Commercialization Milestones [Member] | ADVA Tec Agreement [Member] | Maximum [Member]              
Commitments And Contingencies [Line Items]              
Milestone payments           $ 20,000,000